 |
VasoMedical to Showcase EECP® Therapy and BIOXTM Products at American College of Cardiology’s Annual Scientific Session & Expo |
WESTBURY, N.Y. – March 14, 2014 – VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for non-invasive cardiology – including EECP® Therapy systems, the gold standard of ECP therapy, and ECG Holter and Ambulatory Blood Pressure monitoring products – will exhibit at the American College of Cardiology's 63rd Annual Scientific Session & Expo (ACC.14) from March 29 – 31, 2014 in Washington D.C. VasoMedical has participated in this major event every year since 1995.
The American College of Cardiology's (ACC) Annual Scientific Session & Expo is a annual meeting in which members of the ACC and medical professionals, both domestic and international, come together to share and discuss the latest developments in cardiovascular health and treatment. Attendance at last year's ACC meeting grew 5% with over 13,000 professional attendees participating. More than 300 exhibitors have signed up to exhibit at the three day conference. The event aims to promote the innovative developments and successful practices that impact the delivery of quality care and the prevention of cardiovascular diseases.
VasoMedical will be located in Booth 3003 in the Walter E. Washington Convention Center. The Company will be conducting demonstrations of its core technology, EECP® Therapy and its BIOXTM series products including ECG Holter and ambulatory blood pressure monitors as well as related analysis and reporting software.
“The American College of Cardiology's annual session represents an opportunity for VasoMedical to generate greater acceptance for our products and stay connected with the research and academic community with our continuing participation in the largest gathering of cardiologists and cardiovascular professionals in the U.S.,” said Larry Liebman, Vice President of Sales & Marketing at VasoMedical.
Liebman added, “The ACC and VasoMedical share similar goals, which include advancing education about the development of cardiovascular disease treatments and prevention techniques. At ACC.14 we will highlight the positive impact EECP® Therapy and our patient management products can have on heart disease patients, service providers and payers in the healthcare system today and in the future.”
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273
swolf@kcsa.com / aherweg@kcsa.com